Table 4.
Main studies of anti-HER2 agents
| Study [ref.] | n | Neoadjuvant chemotherapy | Neoadjuvant anti-HER2 agent | Adjuvant therapy | pCR, % |
|---|---|---|---|---|---|
| NOAH [23] | 235 | AP → paclitaxel → CMF | Trastuzumab | trastuzumab | 38 |
| - | 19 | ||||
| GeparQuinto [25] | 615 | EC → docetaxel | trastuzumab | trastuzumab | 22.7 |
| lapatinib | 30.3 | ||||
| NeoALTTO [26] | 455 | paclitaxel | trastuzumab | trastuzumab + FEC | 27.6 |
| lapatinib | lapatinib + FEC | 20 | |||
| trastuzumab + lapatinib | trastuzumab + lapatinib + FEC | 46.8 | |||
| NeoSphere [27] | 417 | docetaxel | trastuzumab | trastuzumab + FEC | 29 |
| docetaxel | trastuzumab + pertuzumab | trastuzumab + FEC | 45.8 | ||
| - | trastuzumab + pertuzumab | trastuzumab + docetaxel → FEC | 16.8 | ||
| docetaxel | pertuzumab | trastuzumab + FEC | 24 | ||
| TRYPHAENA [28] | 225 | FEC → docetaxel | trastuzumab + pertuzumab | trastuzumab | 50.7 |
| FEC → docetaxel | 45.3 | ||||
| docetaxel + carboplatin | 51.9 |
pCR = Pathologic complete response; AP = doxorubicin + cisplatin; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; EC = epirubicin + cyclophosphamide; FEC = 5-fluorouracil, epirubicin, cyclophosphamide.